NCT00002133

Brief Summary

To assess the efficacy and safety of itraconazole oral solution in HIV-seropositive patients with oropharyngeal candidiasis that is refractory to fluconazole.

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Geographic Reach
1 country

18 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 2, 1999

Completed
1.8 years until next milestone

First Posted

Study publicly available on registry

August 31, 2001

Completed
Last Updated

June 24, 2005

Status Verified

April 1, 1996

First QC Date

November 2, 1999

Last Update Submit

June 23, 2005

Conditions

Keywords

ItraconazoleAcquired Immunodeficiency SyndromeAIDS-Related ComplexCandidiasis, Oral

Interventions

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients must have:
  • HIV antibody seropositivity or diagnosis of AIDS.
  • Confirmed oropharyngeal candidiasis.
  • Failed fluconazole treatment within the past 14 days.
  • Life expectancy of at least 3 months.
  • NO symptoms of esophageal candidiasis (e.g., dysphagia) unless endoscopic exam of esophagus was performed and fungal esophagitis was not present.
  • NO prior disseminated candidiasis.

You may not qualify if:

  • Co-existing Condition:
  • Patients with the following symptoms or conditions are excluded:
  • Underlying clinical condition that precludes study completion or places the patient at significant risk.
  • Considered unreliable about following physician's directives.
  • Concurrent Medication:
  • Excluded:
  • Investigational drugs (approved expanded access drugs are permitted).
  • Rifampin.
  • Rifabutin.
  • Phenobarbital.
  • Phenytoin.
  • Carbamazepine.
  • Terfenadine.
  • Astemizole.
  • Patients with the following prior conditions are excluded:
  • +5 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (18)

Univ of Alabama at Birmingham

Birmingham, Alabama, 35294, United States

Location

Univ of Arkansas for Med Sciences

Little Rock, Arkansas, 72205, United States

Location

East Bay AIDS Ctr

Berkeley, California, 94705, United States

Location

Kaiser Permanente Med Ctr

San Francisco, California, 94115, United States

Location

Dr Douglas Ward

Washington D.C., District of Columbia, 20009, United States

Location

George Washington Univ Med Ctr

Washington D.C., District of Columbia, 20037, United States

Location

Veterans Administration Med Ctr

Washington D.C., District of Columbia, 20422, United States

Location

Infectious Diseases Research Clinic / Indiana Univ Hosp

Indianapolis, Indiana, 46202, United States

Location

Natl Inst of Allergy & Infect Dis / Cln Ctr

Bethesda, Maryland, 20892, United States

Location

Ann Arbor Veterans Administration Med Ctr

Ann Arbor, Michigan, 48105, United States

Location

Wayne State Univ / Harper Hosp

Detroit, Michigan, 48201, United States

Location

Washington Univ

St Louis, Missouri, 63108, United States

Location

Ohio State Univ Hosp

Columbus, Ohio, 43210, United States

Location

Oklahoma City Veterans Administration Med Ctr

Oklahoma City, Oklahoma, 73104, United States

Location

Pennsylvania Hosp

Philadelphia, Pennsylvania, 19107, United States

Location

Infectious Disease Clinic

Nashville, Tennessee, 37212, United States

Location

Audie L Murphy Veterans Administration Hosp

San Antonio, Texas, 78284, United States

Location

Univ of Virginia Health Sciences Ctr

Charlottesville, Virginia, 22908, United States

Location

Related Publications (1)

  • Moskovitz B, Wu J, Baruch A, Benken C. Long term safety and efficacy of itraconazole oral solution (IS) for treatment of fluconazole refractory oropharyngeal candidiasis (OC) in HIV-positive patients (pts). Conf Retroviruses Opportunistic Infect. 1997 Jan 22-26;4th:124 (abstract no 325)

    BACKGROUND

MeSH Terms

Conditions

Candidiasis, OralHIV InfectionsAcquired Immunodeficiency SyndromeAIDS-Related Complex

Interventions

Itraconazole

Condition Hierarchy (Ancestors)

CandidiasisMycosesBacterial Infections and MycosesInfectionsMouth DiseasesStomatognathic DiseasesBlood-Borne InfectionsCommunicable DiseasesSexually Transmitted Diseases, ViralSexually Transmitted DiseasesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsVirus DiseasesGenital DiseasesUrogenital DiseasesImmunologic Deficiency SyndromesImmune System DiseasesSlow Virus Diseases

Intervention Hierarchy (Ancestors)

TriazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPiperazines

Study Design

Study Type
interventional
Phase
not applicable
Masking
NONE
Purpose
TREATMENT
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

November 2, 1999

First Posted

August 31, 2001

Last Updated

June 24, 2005

Record last verified: 1996-04

Locations